Pharmaceutical Release of abstracts of presentations to be made at the forthcoming49th Annual Meeting of the American Society of Clinical Oncology (ASCO) meeting by US drug major Bristol-Myers Squibb (NYSE: BMY), notably extended follow-up from a Phase nivolumab study, results from Phase I nivolumab and Yervoy (ipilimumab; which was approved as a treatment for melanoma in 2011) combination study, and five-year survival data from four Phase II Yervoy studies, caused a great deal of excitement in the investment community. 17 May 2013